New vaccine combo aims to outsmart neuroblastoma in high-risk kids
NCT ID NCT04936529
First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 26 times
Summary
This study tests a combination of a bivalent vaccine, a sugar called beta-glucan, and a protein (GM-CSF) to help the immune system fight high-risk neuroblastoma that is in complete remission. About 286 participants will receive the vaccine and beta-glucan, with some also getting GM-CSF to see if it boosts antibody levels. The goal is to prevent the cancer from returning, not to cure it, as ongoing monitoring and potential future treatments are still needed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROBLASTOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-••••
Locations
-
Memorial Sloan Kettering Cancer Center
RECRUITINGNew York, New York, 10065, United States
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.